MARKET

CRBU

CRBU

Caribou Biosciences, Inc.
NASDAQ
0.9999
+0.0490
+5.15%
Pre Market: 0.9998 -0.0001 -0.01% 08:07 03/21 EDT
OPEN
0.9600
PREV CLOSE
0.9509
HIGH
1.020
LOW
0.9501
VOLUME
125
TURNOVER
0
52 WEEK HIGH
5.77
52 WEEK LOW
0.9500
MARKET CAP
93.00M
P/E (TTM)
-0.6057
1D
5D
1M
3M
1Y
5Y
1D
Caribou Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target
Benzinga · 2d ago
Weekly Report: what happened at CRBU last week (0310-0314)?
Weekly Report · 4d ago
U.S. RESEARCH ROUNDUP-Beam Therapeutics, Lennar, Redfin
Reuters · 03/11 07:08
CARIBOU BIOSCIENCES INC <CRBU.O>: RBC CUTS TARGET PRICE TO $11 FROM $14
Reuters · 03/11 04:10
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 03/10 21:15
CARIBOU BIOSCIENCES INC - EXPECTS $249.4 MLN IN CASH, CASH EQUIVALENTS TO FUND OPERATIONS INTO H2 2026
Reuters · 03/10 20:23
CARIBOU BIOSCIENCES INC -QTRLY SHR LOSS $0.39
Reuters · 03/10 20:23
More
About CRBU
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.

Webull offers Caribou Biosciences Inc stock information, including NASDAQ: CRBU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRBU stock methods without spending real money on the virtual paper trading platform.